© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.
Researchers looked at potential drug-drug interactions among Swiss people with HIV and compared them with a cohort from 2008.
People who switched from tenofovir disoproxil fumarate to tenofovir alafenamide gained weight regardless of other meds.
The agency has also lowered the weight threshold for film-coated tablets of the integrase inhibitor.
A rundown of POZ’s reporting on the 2020 Conference on Retroviruses and Opportunistic Infections
Studies have found that weight gain is common after people with HIV begin an antiretroviral in this class.
Weight gain speeds up after switching to an integrase inhibitor from a non-nucleoside reverse transcriptase inhibitor.
Researchers at George Washington University take a look.
Future research should examine how particular combinations of antiretrovirals contribute to weight gain, according to one expert.
However, a recent study found that this varied based on the specific integrase inhibitor used.
This from a small study of people who switched from a boosted protease inhibitor to Isentress (raltegravir) or Tivicay (dolutegravir).
More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
